Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

Volume: 371, Issue: 2, Pages: 299 - 308
Published: Sep 19, 2019
Abstract
Target-engagement pharmacodynamic (PD) biomarkers are valuable tools in the prioritization of drug candidates, especially for novel, first-in-class mechanisms whose robustness to alter disease outcome is unknown. Methionine aminopeptidase 2 (MetAP2) is a cytosolic metalloenzyme that cleaves the N-terminal methionine from nascent proteins. Inhibition of MetAP2 leads to weight loss in obese rodents, dogs and humans. However, there is a need to...
Paper Details
Title
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors
Published Date
Sep 19, 2019
Volume
371
Issue
2
Pages
299 - 308
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.